{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:26:39Z","timestamp":1785518799242,"version":"3.56.0"},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The frequent occurrence of immune-related adverse events during immune checkpoint inhibitor therapy for non\u2013small cell lung cancer (NSCLC), particularly dermatologic toxicities, often necessitates treatment modifications and systemic corticosteroid use, negatively affecting patient outcomes. This study evaluated the impact of a multidisciplinary prophylactic intervention on the incidence of severe skin toxicities among patients receiving nivolumab + ipilimumab (NI) with or without chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>This single-center, retrospective, observational study included 154 treatment-na\u00efve patients with NSCLC who received NI with or without chemotherapy. A comparison was made between skin toxicities and clinical outcomes before and after the implementation of a prophylactic intervention consisting of physician-prescribed medications, pharmacist-led patient education, and nurse-guided skincare. The primary end points were the incidence of grade 3 or higher skin toxicities, systemic corticosteroid use, and treatment discontinuation. Secondary end points included progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The incidence of grade 3 skin toxicities significantly decreased from 21% before the intervention to 8% after the intervention (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .045). Systemic corticosteroid use and treatment discontinuation rates due to skin toxicities reduced from 36% to 10% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0004) and from 21% to 4% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0012), respectively. Patients with any grade of skin rash exhibited significantly improved PFS and OS compared with those without skin toxicities. However, grade 3 toxicities were associated with poor OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Prophylactic interventions significantly reduced the severity of skin toxicities and enhanced treatment continuity in patients with NSCLC receiving nivolumab and ipilimumab\u2013based therapy. These findings underscore the importance of proactive, multidisciplinary management strategies to optimize therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00100","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:59:15Z","timestamp":1751299155000},"page":"602-610","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic Interventions to Prevent Severe Skin Toxicities in Patients With Non\u2013Small Cell Lung Cancer Treated With Nivolumab + Ipilimumab With or Without Chemotherapy"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5878","authenticated-orcid":true,"given":"Toshiyuki","family":"Sumi","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan"},{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Kanamaru","sequence":"additional","affiliation":[{"name":"Nursing Department, Hakodate Goryoukaku Hospital, Hakodate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hakodate Goryoukaku Hospital, Hakodate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahumi","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hakodate Goryoukaku Hospital, Hakodate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Ishigooka","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan"},{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan"},{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan"},{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.010"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100345"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03115-y"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633032"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102365"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02390-2"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.019"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.80272"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.2023047032"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420943260"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546"},{"key":"e_1_3_6_15_2","first-page":"1076","article-title":"Comparison of skin concentrations following topical versus oral corticosteroid treatment: Reconsidering the treatment of common inflammatory dermatoses","volume":"8","author":"McClain RW","year":"2009","unstructured":"McClain RW, Yentzer BA, Feldman SR: Comparison of skin concentrations following topical versus oral corticosteroid treatment: Reconsidering the treatment of common inflammatory dermatoses. J Drugs Dermatol 8:1076-1079, 2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04246.x"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3003"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0356"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872295"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad195"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:08:16Z","timestamp":1778713696000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1200\/OP-25-00100"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00100","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}